Topics

Merck Extends Strategic Collaboration with NGM Bio for Discovery and Development of Novel Biologic Therapeutics

11:46 EDT 20 Mar 2019 | Speciality Pharma Journal

KENILWORTH, N.J., and SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022. The collaboration, …

Original Article: Merck Extends Strategic Collaboration with NGM Bio for Discovery and Development of Novel Biologic Therapeutics

NEXT ARTICLE

More From BioPortfolio on "Merck Extends Strategic Collaboration with NGM Bio for Discovery and Development of Novel Biologic Therapeutics"

Quick Search

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...